Home / Market News / $KNSA

$KNSA news and market catalysts

The 14 most recent market catalysts affecting $KNSA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

14 catalysts 2 high impact 11 bullish 0 bearish Pharmaceuticals
Nov 4, 2026 Corporate Catalyst Neutral Impact 55
Kiniksa Pharmaceuticals International Insider Reports Stock Sale
Kiniksa Pharmaceuticals International, plc reported an insider sale of $9,625,790 worth of company stock. This event is significant because insider selling can sometimes signal a l…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals
Wedbush's decision to raise its price target for Kiniksa Pharmaceuticals to $102 from $99, while maintaining an Outperform rating, indicates a positive re-evaluation of the company…
Oct 22, 2026 Corporate Catalyst Neutral Impact 55
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results
This 8-K filing is a standard disclosure by Kiniksa Pharmaceuticals International, plc, informing investors about an upcoming conference call and webcast to discuss its third-quart…
Oct 22, 2026 Corporate Catalyst Neutral Impact 65
Kiniksa Pharmaceuticals Appoints Ross Moat as President and COO
Kiniksa Pharmaceuticals (KNSA) has appointed Ross Moat as President and COO, effective October 22, 2026. This is a notable executive leadership change, indicating the company's com…
Jul 30, 2026 Corporate Catalyst Bullish Impact 65
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Goldman Sachs analyst Paul Choi maintained a 'Buy' rating on Kiniksa Pharmaceuticals (KNSA) and raised the price target from $75 to $90. This action indicates a strengthened positi…
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107
JP Morgan analyst Anupam Rama has maintained an 'Overweight' rating on Kiniksa Pharmaceuticals (KNSA) and raised the price target from $72 to $107. This substantial increase in the…
Jul 29, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98
Canaccord Genuity's analyst Edward Nash has maintained a 'Buy' rating on Kiniksa Pharmaceuticals and significantly raised the price target from $64 to $98. This action signals incr…
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99
Wedbush analyst David Nierengarten maintained an 'Outperform' rating for Kiniksa Pharmaceuticals and significantly raised the price target from $72 to $99. This action indicates a …
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100
Citigroup analyst Geoff Meacham has maintained a 'Buy' rating on Kiniksa Pharmaceuticals and raised the price target from $60 to $100. This substantial increase in the price target…
Jul 28, 2026 Corporate Catalyst Bullish Impact 85
Kiniksa Pharmaceuticals International shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a strong positive corporate catalyst for Kiniksa Pharmaceuticals. Better-than-expected earnings and, more importantly, a raised long-term sales guidance (F…
Jul 28, 2026 Corporate Catalyst Bullish Impact 92
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate
Kiniksa Pharmaceuticals announced Q2 earnings of $0.30 per share, surpassing the analyst consensus of $0.27 by 11.11%, and representing a 30.43% increase year-over-year. Additional…
Jul 28, 2026 Corporate Catalyst Bullish Impact 75
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (KNSA) filed an 8-K to announce a substantial increase in its sales outlook for fiscal year 2026. The company raised its guidance from $930M-$945M to $980M-…
Jul 23, 2026 Corporate Catalyst Bullish Impact 65
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75
Goldman Sachs analyst Paul Choi has maintained a 'Buy' rating on Kiniksa Pharmaceuticals (KNSA) and raised the price target from $60 to $75. This upgrade signals increased confiden…
Jul 13, 2026 Corporate Catalyst Bullish Impact 65
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74
Wells Fargo analyst Eva Fortea Verdejo maintained an 'Overweight' rating on Kiniksa Pharmaceuticals (KNSA) and significantly raised the price target from $57 to $74. This upward re…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.